LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK), the research-based pharmaceutical and healthcare company, said Friday the World Health Organization has awarded prequalification for global use to Synflorix, GlaxoSmithKline Biologicals' pneumococcal conjugate vaccine.
MAIN FACTS:
-The WHO prequalification allows UN agencies to purchase vaccines on behalf of developing countries and will accelerate global access to Synflorix.
-WHO awarded prequalification for global use to a one-dose vial presentation of Synflorix, which certifies the vaccine's safety profile.
-GSK is working closely with the WHO to review a file for the prequalification of a two-dose vial, a presentation that could make more efficient use of limited refrigeration space in low-resource settings.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com